Literature DB >> 24345329

A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers.

Jon E Grant1, Brian L Odlaug, Samuel R Chamberlain, Marc N Potenza, Liana R N Schreiber, Christopher B Donahue, Suck Won Kim.   

Abstract

OBJECTIVE: Pathological gambling is associated with elevated proportions of nicotine dependence, and tobacco smoking in pathological gamblers has been associated with increased problem-gambling severity. This study examined the addition of N-acetylcysteine to imaginal desensitization in adults with co-occurring nicotine dependence and pathological gambling.
METHOD: Twenty-eight individuals with co-occurring DSM-IV nicotine dependence and pathological gambling who were receiving behavioral therapy were recruited from December 2009 to February 2012 and randomized to augmentation with N-acetylcysteine or placebo in an 12-week, double-blind trial. Subjects were assessed with measures of nicotine and gambling severity and followed for 3 months after treatment. The primary outcomes were the Fagerström Test for Nicotine Dependence and the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale.
RESULTS: During the first 6 weeks, there was a significant benefit of N-acetylcysteine treatment versus placebo on Fagerström Test for Nicotine Dependence total scores (t = -2.224; P = .031). After the initial 6 weeks, all subjects significantly (P < .001) benefited from imaginal desensitization. During the 3-month follow-up, there was a significant additional benefit for N-acetylcysteine versus placebo on measures of problem-gambling severity (t = 2.069; P = .043).
CONCLUSIONS: N-acetylcysteine treatment during therapy facilitates long-term application of behavioral therapy techniques once patients are in the community after therapy has been completed. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00967005. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24345329     DOI: 10.4088/JCP.13m08411

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  27 in total

1.  The placebo effect and its clinical associations in gambling disorder.

Authors:  Jon E Grant; Samuel R Chamberlain
Journal:  Ann Clin Psychiatry       Date:  2017-08       Impact factor: 1.567

2.  A Double-Blind, Randomized, Controlled Pilot Trial of N-Acetylcysteine in Veterans With Posttraumatic Stress Disorder and Substance Use Disorders.

Authors:  Sudie E Back; Jenna L McCauley; Kristina J Korte; Daniel F Gros; Virginia Leavitt; Kevin M Gray; Mark B Hamner; Stacia M DeSantis; Robert Malcolm; Kathleen T Brady; Peter W Kalivas
Journal:  J Clin Psychiatry       Date:  2016-11       Impact factor: 4.384

3.  An Analysis of Treatment-Seeking Behavior in Individuals with Gambling Disorder.

Authors:  Michael D Harries; Sarah A Redden; Jon E Grant
Journal:  J Gambl Stud       Date:  2018-09

4.  Treatment of Gambling Disorders.

Authors:  Sarah W Yip; Marc N Potenza
Journal:  Curr Treat Options Psychiatry       Date:  2014-06-01

Review 5.  Gambling disorder and other behavioral addictions: recognition and treatment.

Authors:  Yvonne H C Yau; Marc N Potenza
Journal:  Harv Rev Psychiatry       Date:  2015 Mar-Apr       Impact factor: 3.732

Review 6.  Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders.

Authors:  Douglas J Roberts-Wolfe; Peter W Kalivas
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

Review 7.  Targeting Mitochondrial Dysfunction for Bipolar Disorder.

Authors:  Maya Kuperberg; Sophie L A Greenebaum; Andrew A Nierenberg
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 8.  The neural bases of cognitive processes in gambling disorder.

Authors:  Marc N Potenza
Journal:  Trends Cogn Sci       Date:  2014-06-22       Impact factor: 20.229

Review 9.  The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis.

Authors:  M D Scofield; J A Heinsbroek; C D Gipson; Y M Kupchik; S Spencer; A C W Smith; D Roberts-Wolfe; P W Kalivas
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 10.  Glial and neuroinflammatory targets for treating substance use disorders.

Authors:  Ryan K Bachtell; Jermaine D Jones; Keith G Heinzerling; Patrick M Beardsley; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2017-08-31       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.